by The global Preeclampsia Diagnostics Market is estimated to be valued at US$ 1587.53 Mn in 2023 and is expected to exhibit a CAGR of 11.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Preeclampsia is a pregnancy complication characterized by high blood pressure and signs of damage to another organ system, most often the liver and kidneys. It is a leading cause of maternal and infant illness and death worldwide. Preeclampsia diagnosis involves identification of signs and symptoms such as protein in urine, high blood pressure, and other serious problems like impaired liver function or low blood platelets. Various diagnostic tests are performed to detect preeclampsia which includes complete blood count, liver and kidney function tests, urine test, coagulation tests, and others. Technologically advanced diagnostics are being adopted for preeclampsia detection which provides quick, accurate, and reliable results. This is expected to drive the growth of the market over the forecast period.
Market key trends:
One of the key trends in the preeclampsia diagnostics market is the development and use of novel biomarker-based tests. Biomarkers offer promise for early and accurate detection of preeclampsia. Companies are engaged in developing tests that can detect preeclampsia by measuring the levels of certain biomarkers in maternal blood during early pregnancy. For instance, Sera Prognostics is developing a multi-protein biomarker test, called PreTRM, for predicting risk of preterm birth, including that due to preeclampsia. Another significant trend is the growing adoption of point-of-care diagnostic devices. Portable and easy-to-use devices enable rapid testing and generation of results at the site of patient care. This eases diagnosis and allows timely clinical management decisions.
Porter’s Analysis
Threat of new entrants: The preeclampsia diagnostics market has moderate threat of new entrants due to established key players and high R&D costs for new product development.
Bargaining power of buyers: The bargaining power of buyers is moderate due to availability of substitutes and rising awareness.
Bargaining power of suppliers: The bargaining power of suppliers is low due to presence of many raw material suppliers.
Threat of new substitutes: The threat of new substitutes is low as there are limited substitutes for preeclampsia diagnostics.
Competitive rivalry: The competition in the market is high due to presence of many key players.
Key Takeaways
The global Preeclampsia Diagnostics Market is expected to witness high growth, exhibiting CAGR of 11% over the forecast period, due to increasing adoption of prenatal screening methods.
Regional analysis
North America is expected to dominate the global preeclampsia diagnostics market over the forecast period due to rising healthcare expenditure and presence of major players. Asia Pacific exhibits the fastest growth during the forecast period owing to growing awareness regarding pregnancy complications, rising healthcare expenditure and improving healthcare infrastructure.
Key players
Key players operating in the preeclampsia diagnostics market are Diabetomics, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, PerkinElmer Inc., Siemens Healthineers AG, DRG INSTRUMENTS GMBH, Metabolomic Diagnostics Ltd., Sera Prognostics, MOMM Diagnostics, Miraculins Inc.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Ravina Pandya, a content writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemicals and materials, etc. With an MBA in E-commerce, she has expertise in SEO-optimized content that resonates with industry professionals.
